BeOne Medicines Ltd. (ONC)
Nasdaq · American depositary receipt · Pharmaceutical Preparations
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ONC in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ONC and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ONC at a glance
Key statistics
$43.50B
Market capitalization
- Previous close
- $384.50
- Open
- $382.22
- Day range
- $381.94 – $388.51
- Volume
- 371.1K
- Average volume (30 sessions)
- 403.2K
- Shares outstanding
- 109.79M
- Price / earnings
- 66.3
- Earnings per share
- $5.80
- Price / book
- 8.4
- Price / sales
- 7.1
- Beta (1 year, vs SPY)
- 0.81
Where the price sits in its year
52-week range
100% of the range
- Below the 52-week high
- -0.1%
- Above the 52-week low
- +52.9%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $362.13+6.2%
- 50-day average
- $361.16+6.5%
- 200-day average
- $323.24+19.0%
Between the conventional 30 and 70 bands.
+10.1%
1 week
+5.1%
1 month
+20.2%
3 months
+26.6%
Year to date
+21.5%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ONC
ONC on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ONC.
See the plans →
Every planScreen names like ONC
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ONC
Put ONC on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ONC
See whether there is an open premium alert on ONC, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ONC headlines
- BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features
Benzinga · Dec 7, 2025
- BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients
Benzinga · Aug 29, 2025
SEC Form 4, most recent first
Insider filings
Wang Xiaodong
−10.4K
Director · Open-market sale
$3.63M · Oct 13, 2026
Wang Xiaodong
−403.4K
Director · Option exercise
· Oct 13, 2026
Wang Xiaodong
−5.7K
Director · Open-market sale
$2.00M · Oct 13, 2026
Wang Xiaodong
+31.0K
Director · Option exercise
$1.14M · Oct 13, 2026
Wang Xiaodong
−1.3K
Director · Open-market sale
$445.08K · Oct 13, 2026
Wang Xiaodong
−7.2K
Director · Open-market sale
$2.51M · Oct 13, 2026
Wang Xiaodong
−6.6K
Director · Open-market sale
$2.31M · Oct 13, 2026
Lee Chan Henry
−1.1K
SVP, General Counsel · Open-market sale
$418.13K · Sep 30, 2026
About BeOne Medicines Ltd.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
- Exchange
- Nasdaq
- Security
- American depositary receipt
- Industry
- Pharmaceutical Preparations
- Headquarters
- Basel
- Employees
- 12,000
- Listed since
- Feb 3, 2016
- Website
- beonemedicines.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.